Cointime

ESSA Pharma

company

About

ESSA Pharma is a biotechnology company that develops new drugs for prostate cancer.

  • 1 - 10

Highlights

Total Funding Amount
$55.89M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$55.89M
Industries
Biopharma,Biotechnology,Pharmaceutical
Founded date
Jan 1, 2009
Number Of Employee
1 - 10
Operating Status
Active

ESSA is a pharmaceutical company focused on the development of small molecule drugs for the treatment of cancer, with a focus on advanced prostate cancer. ESSA is developing drugs that selectively block the N-terminal domain of the androgen receptor (AR). The AR is required for the growth and survival of most prostate cancer; therefore, the AR N-terminal domain is an ideal target for next-generation hormone therapy.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$55.89M
ESSA Pharma has raised a total of $55.89M in funding over 2 rounds. Their latest funding was raised on Aug 10, 2020 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 10, 2020 Post-IPO Equity $55.89M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
ESSA Pharma is funded by 1 investors. Pfizer are the most recent investors.
Investor Name Lead Investor Funding Round
Pfizer — Post-IPO Equity
Cointime
İçerikler
Şirket.